Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021

被引：76

作者：

Fabiani, Massimo ^{[1
]}

Ramigni, Mauro ^{[2
]}

Gobbetto, Valentina ^{[2
]}

Mateo-Urdiales, Alberto ^{[1
,3
]}

Pezzotti, Patrizio ^{[1
]}

Piovesan, Cinzia ^{[2
]}

机构：

[1] Ist Super Sanita, Dept Infect Dis, Rome, Italy

[2] Local Hlth Unit ULSS 2 Marca Trevigiana, Treviso, Italy

[3] European Ctr Dis Prevent & Control ECDC, European Programme Intervent Epidemiol Training E, Stockholm, Sweden

来源：

EUROSURVEILLANCE | 2021年 / 26卷 / 17期

关键词：

D O I：

10.2807/1560-7917.ES.2021.26.17.2100420

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Data on effectiveness of the BioNTech/Pfizer COVID-19 vaccine in real-world settings are limited. In a study of 6,423 healthcare workers in Treviso Province, Italy, we estimated that, within the time intervals of 14-21 days from the first and at least 7 days from the second dose, vaccine effectiveness in preventing SARS-CoV-2 infec-tion was 84% (95% confidence interval (CI): 40-96) and 95% (95% CI: 62-99), respectively. These results could support the ongoing vaccination campaigns by providing evidence for targeted communication.

引用

页码：1 / 7

页数：7

共 11 条

[1] Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients [J].

Amit, Sharon ;

Regev-Yochay, Gili ;

Afek, Arnon ;

Kreiss, Yitshak ;

Leshem, Eyal .

LANCET, 2021, 397 (10277) :875-877

[2] Impact of a Nationwide Lockdown on SARS-CoV-2 Transmissibility, Italy [J].

Guzzetta, Giorgio ;

Riccardo, Flavia ;

Marziano, Valentina ;

Poletti, Piero ;

Trentini, Filippo ;

Bella, Antonino ;

Andrianou, Xanthi ;

Del Manso, Martina ;

Fabiani, Massimo ;

Bellino, Stefania ;

Boros, Stefano ;

Urdiales, Alberto Mateo ;

Vescio, Maria Fenicia ;

Piccioli, Andrea ;

Brusaferro, Silvio ;

Rezza, Giovanni ;

Pezzotti, Patrizio ;

Ajelli, Marco ;

Merler, Stefano .

EMERGING INFECTIOUS DISEASES, 2021, 27 (01) :267-270

[3]

Hall VJ, 2021, LANCET

[4]

Istituto Superiore di Sanita, 2022, Informazioni privacy per la sorveglianza sanitaria integrata COVID-19

[5]

Italian Medicines Agency (AIFA), BIONTECH PFIZ VACC A

[6]

Italian Ministry of Health, COV 19 NEW MIN DECR

[7]

Lee K, 2009, GLOB INST, P1

[8]

Manica M., 2021, IMPACT TIERED RESTRI, DOI [10.1101/2021.01.10.21249532, DOI 10.1101/2021.01.10.21249532]

[9] Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine [J].

Polack, Fernando P. ;

Thomas, Stephen J. ;

Kitchin, Nicholas ;

Absalon, Judith ;

Gurtman, Alejandra ;

Lockhart, Stephen ;

Perez, John L. ;

Perez Marc, Gonzalo ;

Moreira, Edson D. ;

Zerbini, Cristiano ;

Bailey, Ruth ;

Swanson, Kena A. ;

Roychoudhury, Satrajit ;

Koury, Kenneth ;

Li, Ping ;

Kalina, Warren V. ;

Cooper, David ;

Frenck, Robert W., Jr. ;

Hammitt, Laura L. ;

Tureci, Ozlem ;

Nell, Haylene ;

Schaefer, Axel ;

Unal, Serhat ;

Tresnan, Dina B. ;

Mather, Susan ;

Dormitzer, Philip R. ;

Sahin, Ugur ;

Jansen, Kathrin U. ;

Gruber, William C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (27) :2603-2615

[10]

Public Health England (PHE), ANN A REP JCVI EST E

← 1 2 →